HS and IBD share clinical, genetic, and immunological characteristics, including cytokine abnormalities like elevated IL-1, IL-6, IL-17, IL-23, and TNF, linking them to a higher prevalence of SpA responsive to TNF inhibitors (35). This evidence concerns the gene IL17A and inflammatory bowel disease.